Phase 3 Clinical Trials in 2017

2017 Phase 3 Research Overview

Phase 3 clinical trials started in 2017 provide a snapshot of the medical research landscape. In total, 9 such trials were initiated. 1 of these are still actively recruiting. 2 trials have been completed. Leading sponsors include National Cancer Institute (NCI), Daehwa Pharmaceutical Co., Ltd., Genzyme, a Sanofi Company.

Phase 3 Trials

Recruiting

Trial Status

ACTIVE NOT RECRUITING: 5 trials
COMPLETED: 2 trials
TERMINATED: 1 trial
RECRUITING: 1 trial

Phase 3 Trials Started in 2017

A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer

NCT03315364 · ACTIVE NOT RECRUITING · Phase 3 · Daehwa Pharmaceutical Co., Ltd.

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

NCT03368664 · TERMINATED · Phase 3 · Genzyme, a Sanofi Company

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

NCT03233191 · ACTIVE NOT RECRUITING · Phase 3 · ECOG-ACRIN Cancer Research Group

Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

NCT03736161 · COMPLETED · Phase 3 · Globe Pharmaceuticals Limited

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

NCT02839707 · ACTIVE NOT RECRUITING · Phase 3 · National Cancer Institute (NCI)

An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.

NCT02962414 · ACTIVE NOT RECRUITING · Phase 3 · Novartis Pharmaceuticals

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181 · RECRUITING · Phase 3 · Children's Oncology Group

Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy

NCT02840175 · COMPLETED · Phase 3 · Assistance Publique - Hôpitaux de Paris

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

NCT02954874 · ACTIVE NOT RECRUITING · Phase 3 · National Cancer Institute (NCI)

Frequently Asked Questions

How many Phase 3 trials started in 2017?

9 Phase 3 clinical trials were started in 2017 according to ClinicalTrials.gov data tracked by ReadTheTrial.

What is Phase 3 in clinical trials?

Phase 3 trials are large-scale pivotal studies with 300-3,000+ participants for FDA approval.

Are any 2017 Phase 3 trials recruiting?

Yes, 1 Phase 3 trials from 2017 are still recruiting.